Skip to main content
Beijing Beilu Pharmaceutical Co.,Ltd logo

Beijing Beilu Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 300016 ISIN · CNE000001QK9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,003 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300016

About Beijing Beilu Pharmaceutical Co.,Ltd

https://www.beilu.com.cn

Beijing Beilu Pharmaceutical Co.,Ltd. specializes in the research, development, production, and distribution of specialized pharmaceutical products. The company is a leading provider of contrast media, offering a comprehensive range of diagnostic imaging agents for magnetic resonance imaging (MRI) and computed tomography (CT) scans, including Gadopentetate Dimeglumine, Iohexol, and Iodixanol. Beyond its core diagnostic portfolio, the firm develops and markets treatments for central nervous system disorders, notably its proprietary Jiuwei Zhenxin Granules for the treatment of generalized anxiety disorder. Its product lineup also extends to metabolic health, featuring medications such as Repaglinide for the management of type 2 diabetes. The company focuses on technological innovation and stringent quality standards to serve clinical needs in diagnostic medicine and specialized therapeutic areas.

Recent filings

Filing Released Lang Actions
北京市中伦律师事务所关于北京北陆药业股份有限公司2025年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) issued by an external law firm regarding the legality of convening, procedures, attendees’ qualifications and voting results of the company’s 2025 Annual General Meeting. It does not itself present financial statements, management discussion, proxy materials, or the company’s own voting results notice, but serves as a compliance/legal attestation. There is no separate category for a legal opinion letter, so it falls under the general “Regulatory Filings” (RNS) fallback.
2026-05-25 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement detailing the convening of the 2025 annual shareholders’ meeting, the attendance, each resolution put to vote and the vote counts (agree/oppose/abstain), and it closes with the legal opinion. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA), which covers official results from shareholder votes at any general meeting.
2026-05-25 Chinese
关于召开2025年度股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice to shareholders describing the convening of the 2025 Annual General Meeting, including meeting time, location, agenda items, registration and proxy voting procedures, and accompanying forms (proxy form, registration form, voting instructions). This is not the actual minutes or results but solicits votes and provides information for proxy voting. Therefore, it aligns with the definition of a Proxy Solicitation & Information Statement.
2026-05-24 Chinese
关于高级管理人员减持股份的预披露公告
Director's Dealing Classification · 95% confidence The document is an official announcement by Beijing Beilu Pharmaceutical Co., Ltd. about a senior management (vice general manager) planned reduction of personal shareholdings. It details the insider’s current holdings, planned decrease, compliance with regulations, and timing. This fits the definition of a Director's Dealing report (insider transactions).
2026-05-20 Chinese
关于使用暂时闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 82% confidence The document is a formal announcement (“公告”) by Beijing Beilu Pharmaceutical Co., Ltd. regarding the use of temporarily idle IPO proceeds (募集资金) for cash management. It details board resolutions, raised‐funds background, investment limits, risk controls and sponsor opinions. It is an operational/regulatory disclosure, not an actual financial report (e.g., interim report or annual report), earnings release, or a standalone audit. It does not fit any more specific category (e.g., financing/CAP deals with new fundraising, SHA deals with share issues, POS with share repurchases). Thus it falls under general regulatory filings disclosures.
2026-05-18 Chinese
中信建投证券股份有限公司关于北京北陆药业股份有限公司使用暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 75% confidence The document is a sponsor’s verification opinion (“核查意见”) on the company’s usage of temporarily idle fundraising proceeds for cash management. It is not an earnings release, capital raise announcement, board change, audit or financial report, nor a proxy or dividend notice. Rather, it is a mandatory regulatory disclosure under Shenzhen Stock Exchange rules and CSRC regulations. It does not itself present full financial statements or function as the actual fundraising or investment report, but is a compliance filing. Therefore it falls under the general regulatory filings category (RNS).
2026-05-18 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.